Calgary Transit Is En-Route With Access-IS Ticket Validators
Access-IS, part of HID, the leading supplier of software agnostic ticket validators is excited to announce the integration of its VAL100 devices by Masabi. The integration is part of Masabi’s My Fare solution, a contactless mobile ticketing app for Calgary Transit that lets passengers buy tickets and passes anytime, anywhere, using their smartphones. It’s fast, easy, contactless and a safe way to pay and ride transit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005015/en/
Access-IS VAL100 ticket validator alongside Masabi’s My Fare solution (Photo: Business Wire)
The My Fare app, which is powered by Masabi’s Justride platform and can be downloaded from the App Store and Google Play, allows riders of Calgary Transit services to purchase and use fare products such as regular monthly and day passes, airport boarding pass, and single ride tickets directly from their mobile device.
As part of the project over 1000 Access-IS VAL100 ticket validators have been installed across the bus network covering 155 routes. Passengers scan their dynamic and encrypted mobile passes on the devices when boarding the bus, with an audible beep and a colored screen identifying the ticket as valid for use. These validation units will help speed up boarding times making riding Calgary Transit services faster and safer by enabling contactless fare payment and validation. The validation units are powered by Masabi’s Justride Inspect software but also read NFC and contactless EMV (cEMV) technology, giving the agency the flexibility to turn on Account-Based Ticketing and other account-based tokens, if required.
“Calgarians, like citizens in towns and cities around the world, are using smartphones in almost all aspects of their day and made offering the option for riders to use their phone instead of a paper ticket a logical step for Calgary Transit,” said Brian Zanghi, CEO of Masabi. “The change in people’s behaviour brought about by the current requirement for social distancing has made mobile ticketing and the move towards a more contactless journey experience a must-have for transit agencies.”
The VAL100 combines barcode and NFC/RFID reading functionality to provide a single point of presentation for tickets and travel passes – whether presented on a paper ticket, smartcard or mobile phone. It is also available with EMV Level 2 certification, allowing for applications where contactless payments are required. It offers PCI and SRED compliance for contactless payments using VISA, MasterCard, AMEX and Discover payment schemes. It features clear visual and audio passenger feedback, a robust design and a wide range of connection options for installation flexibility.
Speaking about the installation, Bryan Cunningham Regional Sales Manager (Americas) at Access-IS said “It’s always a pleasure to work with Masabi to deliver a ticketing and fare payment solution focused on providing the very best passenger experience whilst protecting the transits agency’s ability to manage fare revenue.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201027005015/en/
Contact information
Andrew Covey
+44(0)118-966-3333
Andrew.Covey@access-is.com
www.access-is.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 09:42:00 EET | Press release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 09:30:00 EET | Press release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 04:06:00 EET | Press release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom